Checkpoint Therapeutics (CKPT) Competitors $3.20 +0.04 (+1.27%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CKPT vs. IMNM, OCS, EOLS, AUTL, RAPP, TRDA, KURA, DNA, CRGX, and KROSShould you be buying Checkpoint Therapeutics stock or one of its competitors? The main competitors of Checkpoint Therapeutics include Immunome (IMNM), Oculis (OCS), Evolus (EOLS), Autolus Therapeutics (AUTL), Rapport Therapeutics (RAPP), Entrada Therapeutics (TRDA), Kura Oncology (KURA), Ginkgo Bioworks (DNA), CARGO Therapeutics (CRGX), and Keros Therapeutics (KROS). These companies are all part of the "pharmaceutical products" industry. Checkpoint Therapeutics vs. Immunome Oculis Evolus Autolus Therapeutics Rapport Therapeutics Entrada Therapeutics Kura Oncology Ginkgo Bioworks CARGO Therapeutics Keros Therapeutics Checkpoint Therapeutics (NASDAQ:CKPT) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations, institutional ownership and risk. Which has better valuation & earnings, CKPT or IMNM? Checkpoint Therapeutics has higher earnings, but lower revenue than Immunome. Checkpoint Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCheckpoint Therapeutics$47K3,272.85-$51.85M-$1.84-1.71Immunome$10.13M60.64-$106.81M-$8.11-1.21 Is CKPT or IMNM more profitable? Checkpoint Therapeutics has a net margin of 0.00% compared to Immunome's net margin of -3,014.59%. Checkpoint Therapeutics' return on equity of 0.00% beat Immunome's return on equity.Company Net Margins Return on Equity Return on Assets Checkpoint TherapeuticsN/A N/A -659.07% Immunome -3,014.59%-48.63%-41.62% Does the MarketBeat Community believe in CKPT or IMNM? Checkpoint Therapeutics received 149 more outperform votes than Immunome when rated by MarketBeat users. However, 73.81% of users gave Immunome an outperform vote while only 67.42% of users gave Checkpoint Therapeutics an outperform vote. CompanyUnderperformOutperformCheckpoint TherapeuticsOutperform Votes18067.42% Underperform Votes8732.58% ImmunomeOutperform Votes3173.81% Underperform Votes1126.19% Do analysts recommend CKPT or IMNM? Checkpoint Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 280.95%. Immunome has a consensus price target of $28.83, indicating a potential upside of 193.02%. Given Checkpoint Therapeutics' higher possible upside, research analysts plainly believe Checkpoint Therapeutics is more favorable than Immunome.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Checkpoint Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Immunome 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in CKPT or IMNM? 22.0% of Checkpoint Therapeutics shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 2.1% of Checkpoint Therapeutics shares are held by insiders. Comparatively, 8.6% of Immunome shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer CKPT or IMNM? In the previous week, Checkpoint Therapeutics had 1 more articles in the media than Immunome. MarketBeat recorded 7 mentions for Checkpoint Therapeutics and 6 mentions for Immunome. Checkpoint Therapeutics' average media sentiment score of 1.67 beat Immunome's score of 1.25 indicating that Checkpoint Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Checkpoint Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Immunome 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, CKPT or IMNM? Checkpoint Therapeutics has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Comparatively, Immunome has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. SummaryCheckpoint Therapeutics beats Immunome on 9 of the 17 factors compared between the two stocks. Get Checkpoint Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CKPT vs. The Competition Export to ExcelMetricCheckpoint TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$153.82M$6.62B$5.29B$8.77BDividend YieldN/A2.91%5.07%4.00%P/E Ratio-1.7110.3186.3216.78Price / Sales3,272.85186.451,119.62114.08Price / CashN/A57.6843.2437.77Price / Book-6.704.965.084.86Net Income-$51.85M$153.41M$121.83M$227.32M7 Day Performance-13.93%-6.58%-3.96%-4.54%1 Month Performance-14.17%-1.32%-0.12%-0.19%1 Year Performance62.37%-3.36%24.08%12.92% Checkpoint Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CKPTCheckpoint Therapeutics4.0501 of 5 stars$3.20+1.3%$12.00+275.0%+62.9%$156.27M$47,000.00-1.7410Analyst ForecastShort Interest ↑Positive NewsIMNMImmunome1.777 of 5 stars$11.40+1.2%$28.83+152.9%-19.5%$711.55M$10.13M-1.4140Analyst ForecastShort Interest ↑News CoverageGap DownOCSOculis2.1461 of 5 stars$17.55-0.1%$29.20+66.4%+87.5%$710.85M$980,000.00-9.092Short Interest ↑Gap UpEOLSEvolus3.845 of 5 stars$11.04-4.2%$23.00+108.3%-5.2%$699.06M$248.33M-12.13170Positive NewsAUTLAutolus Therapeutics3.079 of 5 stars$2.62-2.2%$10.40+296.9%-67.2%$697.17M$10.09M-2.17330Analyst ForecastShort Interest ↑News CoveragePositive NewsRAPPRapport Therapeutics1.9546 of 5 stars$18.79-3.5%$35.00+86.3%N/A$687.26MN/A0.00N/ANews CoverageGap DownTRDAEntrada Therapeutics2.4064 of 5 stars$18.34+0.2%$25.67+39.9%-10.5%$686.28M$215.23M11.53110KURAKura Oncology4.3217 of 5 stars$8.66-0.8%$29.86+244.8%-52.4%$673.44MN/A-3.67142Short Interest ↑DNAGinkgo Bioworks0.5919 of 5 stars$11.66+1.0%$4.58-60.8%N/A$670.21M$217.11M-0.891,218Gap DownCRGXCARGO Therapeutics1.6866 of 5 stars$14.37-5.0%$31.80+121.3%-33.9%$661.42MN/A-3.37116Positive NewsGap DownKROSKeros Therapeutics2.917 of 5 stars$16.22+0.7%$75.00+362.4%-72.1%$657.02M$651,000.00-3.11100Short Interest ↑Gap Down Related Companies and Tools Related Companies Immunome Competitors Oculis Competitors Evolus Competitors Autolus Therapeutics Competitors Rapport Therapeutics Competitors Entrada Therapeutics Competitors Kura Oncology Competitors Ginkgo Bioworks Competitors CARGO Therapeutics Competitors Keros Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CKPT) was last updated on 1/13/2025 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkpoint Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Checkpoint Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
